Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Computer Simulation In Drug Development Helps Reducing Animal Tests

21.11.2005


Scientists at the Technische Universität Dresden/Germany are significantly involved in a European research project entitled “BioSim“ which aims at utilising biosimulation as a new tool in drug development. The use of computer simulations will provide more objective data which helps to develop drug compounds more effectively and to reduce investment in drug development drastically. Above all the number of animal tests as well as clinical studies with volunteers will decrease substantially.



“We intend to translate the existing knowledge of drug metabolism and the operating modes of several organs into mathematical models. These serve to perform complex computer simulations of the involved biochemical processes”, says assistant professor Dr Martin Bertau, biochemist at the Department of Chemistry and Food Chemistry at the Technische Universität Dresden.

The highly ambitious scientific “Network of excellence“ – also called “BioSim” – has been funded with 10.7 million euros by the European Union for a five year period since December 2004 and brings together internationally leading European research groups in the fields of life sciences, medicine and mathematics. The activities are coordinated by Professor Erik Mosekilde, Institute of Physics at the Danish University of Technology in Kgs. Lyngby. On the part of the pharmaceutical industry Apogepha Arzneimittel GmbH is involved in Dresden. The network is completed by European regulatory agencies as well as the European Federation of Pharmaceutical Sciences.


In addition to a model of drug metabolism the European activities comprise approaches to the biosimulation of diabetes, cardiac arrhythmia, neurologic/psychiatric disorders and tumor diseases.

At the TU Dresden, a working group of nine scientists headed by assistant professor Dr Martin Bertau of the Institute of Biochemistry as well as researchers from the Institute of High-Performance Computing participate in “BioSim“. Recently, their novel approach in predicting drug metabolism has been successfully demonstrated, using the model drug compound chloramphenicol.

PD Dr Martin Bertau | alfa
Further information:
http://www.tu-dresden.de

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>